Campath

DRUG17 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), EMagnusson, OHSU Knight Cancer Institute, Gruppo Italiano Malattie EMatologiche dell'Adulto, M.D. Anderson Cancer Center

Conditions

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaAdvanced Hematologic MalignanciesAnemia, AplasticAplastic AnemiaChronic Lymphocytic LeukemiaChronic Myelogenous LeukemiaDiffuse Large B-Cell Lymphoma

Phase 1

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

CompletedNCT00047060

National Heart, Lung, and Blood Institute (NHLBI)Mycosis Fungoides, Sezary Syndrome

Start: 2002-07-30End: 2019-01-24Updated: 2023-11-14

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

TerminatedNCT00579111

Baylor College of MedicineAcute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia +5

Start: 2007-06-30End: 2010-10-31Updated: 2016-05-04

Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

TerminatedNCT00684255

New York Medical CollegeSystemic Lupus Erythematosus, Systemic Sclerosis

Start: 2007-08-31End: 2008-07-31Updated: 2014-04-01

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

TerminatedNCT00943293

University of ChicagoGraft Versus Host Disease, Lymphoma, Myeloma +2

Start: 2003-05-31End: 2012-01-31Updated: 2014-03-17

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

CompletedNCT00943319

University of ChicagoLeukemia, Lymphoma, Myeloma

Start: 2012-03-31End: 2018-12-31Updated: 2019-02-04

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

CompletedNCT00943592

University of ChicagoAdvanced Hematologic Malignancies, Leukemia, Preleukemia

Start: 2006-03-31End: 2013-11-30Updated: 2014-02-27

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

RecruitingNCT07015684

Columbia UniversitySickling Disorder Due to Hemoglobin S

Start: 2025-04-28End: 2032-03-12Target: 24Updated: 2025-06-11

Phase 2

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

TerminatedNCT00416884

OHSU Knight Cancer InstituteLeukemia

Start: 2003-05-31End: 2008-03-31Updated: 2017-09-27

Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia

CompletedNCT00462332

Gruppo Italiano Malattie EMatologiche dell'AdultoLeukemia

Start: 2007-05-31End: 2011-06-30Updated: 2013-09-06

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

TerminatedNCT00505921

M.D. Anderson Cancer CenterLymphoma

Start: 2003-03-31End: 2009-11-30Updated: 2011-11-16

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

TerminatedNCT00578903

Baylor College of MedicineAplastic Anemia

Start: 2002-02-28End: 2012-07-31Updated: 2016-04-22

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

CompletedNCT00683046

University of ChicagoAcute Myelogenous Leukemia, Anemia, Aplastic, Chronic Lymphocytic Leukemia +6

Start: 2001-11-30End: 2014-12-31Updated: 2016-11-22

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

CompletedNCT01030900

National Cancer Institute (NCI)Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma

Start: 2009-10-22End: 2021-08-06Updated: 2022-10-06

Phase 3

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

CompletedNCT00564512

French Innovative Leukemia OrganisationLeukemia

Start: 2007-11-30End: 2013-07-31Updated: 2013-07-25

Phase 4

CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

CompletedNCT00246129

EMagnussonKidney Diseases, Kidney Failure, Kidney Transplantation

Start: 2005-10-31End: 2011-06-30Updated: 2021-09-29

Unknown Phase

Campath Maintenance in Chronic Lymphocytic Leukemia

TerminatedNCT00587847

Northwell HealthChronic Lymphocytic Leukemia

Start: 2005-08-31End: 2009-11-30Updated: 2015-10-15

Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis

WithdrawnNCT01639573

Children's Hospital Los AngelesScleroderma

Start: 2011-04-30End: 2018-09-02Updated: 2023-09-13

Related Papers

Outpatient allogeneic hematopoietic cell transplant following alemtuzumab based reduced intensity conditioning in patients with advanced mycosis fungoides/Sezary syndrome.

Journal of Clinical Oncology2015-05-203 citations

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

2012-02-1465 citations